AUPH — Aurinia Pharmaceuticals Inc. stock price, charts and financials

QT71Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
14.93
+0.36+2.47%
OverviewShort InterestFilings
AUPHQT71Aurinia Pharmaceuticals Inc.·NASDAQ
14.93+2.47%
TA
Loading chart...
Signal & projected range
QT Score downgradeHistorical pattern — not a prediction
Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
MESO+2.28%$14.80URGN+3.45%$39.92TSHA+7.27%$6.20TYRA+1.53%$32.53STOK+7.14%$31.67OCUL+2.26%$8.59GENB-0.42%$14.28IOVA+0.93%$4.36
Snapshot
Index-P/E6.75EPS (ttm)2.16Insider Own15.68%Shs Outstand128.60MPerf Week-4.27%
Market Cap1.87BForward P/E11.88EPS next Y1.23Insider Trans8.50%Shs Float126.24MPerf Month-6.66%
Enterprise Value1.54BPEG0.32EPS next Q0.24Inst Own-Short Float7.70%Perf Quarter-5.08%
Income299.00MP/S6.29EPS this Y-56.02%Inst Trans-Short Ratio6.52Perf Half Y0.28%
Sales298.00MP/B3.30EPS next Y29.05%ROA41.19%Short Interest9.71MPerf YTD-8.65%
Book/sh4.42P/C4.94EPS next 5Y20.98%ROE64.48%52W High19.73 -24.31%Perf Year57.68%
Cash/sh2.95P/FCF11.56EPS past 3/5Y-ROIC18.99%52W Low9.56 56.16%Perf 3Y31.62%
Dividend Est.-EV/EBITDA9.54Sales past 3/5Y28.30% 41.44%Gross Margin89.74%Volatility3.43% 3.58%Perf 5Y33.30%
Dividend TTM-EV/Sales5.18EPS Y/Y TTM5396.18%Oper. Margin41.73%ATR (14)0.61Perf 10Y380.86%
Dividend Ex-Date-Quick Ratio5.01Sales Y/Y TTM26.81%Profit Margin99.97%RSI (14)35.89Recom2.27
Dividend Gr. 3/5Y-Current Ratio5.55EPS Q/Q56.25%SMA20-6.44%Beta1.38Target Price12.60
Payout0.00%Debt/Eq0.10Sales Q/Q25.81%SMA50-8.38%Rel Volume0.94Prev Close14.57
Employees128LT Debt/Eq0.10EarningsOct 29SMA200-3.95%Avg Volume1.49MPrice14.93
IPO DateSep 03, 2014Option/ShortYes / YesEPS/Sales Surpr.28.21% 0.94%Net Debt/EBITDA0.17Volume1,402,439Change2.47%
Analyst Ratings
DateActionAnalystRatingTarget
Dec-03-25DowngradeLeerink PartnersOutperform → Market Perform$16
Nov-07-25UpgradeJefferiesHold → Buy
Nov-05-25DowngradeRBC CapitalOutperform → Sector Perform$15
Nov-05-25DowngradeRBC Capital MktsOutperform → Sector Perform
Sep-06-24ReiteratedHC Wainwright & Co.Buy$26 → $13
May-02-24ReiteratedJefferies$6.00
Jan-04-23ReiteratedRBC CapitalOutperform$22 → $11
Nov-04-22DowngradeOppenheimerOutperform → Perform
Aug-09-22ReiteratedHC Wainwright & Co.Buy$30 → $26
Aug-08-22ReiteratedOppenheimerOutperform$13
Latest News
Jul-24-26
Jul-24-2605:00AM
Top Healthcare Stocks Beyond The Market Rotation Averaging 128% Forward EPS GrowthSeekingAlpha
Jul-23-26
Jul-23-2603:15PM
Playing The Biotech Breakout With Insidersseekingalpha.com
Jul-22-26
Jul-22-2612:20PM
The Credit Cycle Is Flashing YellowSeekingAlpha
Jul-06-26
Jul-06-2609:00AM
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritisgurufocus.com
Jul-02-26
Jul-02-2601:01PM
Aurinia (AUPH) Upgraded to Strong Buy: Here's Whyzacks.com
Jun-26-26
Jun-26-2608:59AM
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and MarkerYahoo
Jun-25-26
Jun-25-2612:40PM
5 Small Drug Stocks to Invest in Amid a Biotech ComebackYahoo
Jun-23-26
Jun-23-2611:08AM
Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?Yahoo
Jun-16-26
Jun-16-2609:10AM
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Screens as Strong Candidate Based on Minervini Trend Template and High Growth Momentum RatingChartMill
Company

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue298283235176134465000
Cost of Goods Sold Incl. D&A31332814610041
Gross Profit26825020716112845500-41
Selling, General and Administrative Excl. Other103102172195196171972214
Research and Development333321504551505341
Other Operating Expense710198-137162
Operating Income124105-5-92-111-181-104-91-56
Interest Expense945300000
Unusual Expense
—————————
Non-Operating Income (Expense)181417175123-8
Net Income Before Taxes1341147-77-106-180-103-88-64
Income Taxes-164-1732121000
Consolidated Net Income2992876-78-108-181-103-88-64
Net Income From Continuing Operations2992876-78-108-181-103-88-64
Net Income2992876-78-108-181-103-88-64
EPS (Recurring)2.242.140.04-0.54-0.76-1.40-0.87-1.33-0.76
EPS (Basic, Before Extraordinaries)2.242.140.04-0.54-0.76-1.40-0.87-1.33-0.76
EPS (Diluted)2.162.070.04-0.54-0.76-1.40-0.87-1.33-0.76
EBITDA16212832-63-104-177-103-90-54
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio6.917.71228.50——————
Price To Sales Ratio6.617.555.467.304.5864.1432.64——
Gross Margin89.9388.3488.0991.4895.5297.83100.00——
Operating Margin41.6137.10-2.13-52.27-82.84-393.48-208.00——
Net Margin100.34101.412.55-44.32-80.60-393.48-206.00——
Shares Outstanding1321341431431421291189385
Market Capitalization1,9712,1371,2841,2866132,9501,6321,884580
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$20.29$16.67$13.04$9.42$5.80● Close Price0.00M3.40M6.79M10.19M13.59MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
TANG KEVINChief Executive OfficerJun 02 '26Buy15.28206,0053,147,75613,044,106Jun 02
TANG KEVINChief Executive OfficerJun 01 '26Buy15.28343,6205,250,52012,838,101Jun 02
TANG KEVINChief Executive OfficerMay 29 '26Buy15.31264,9814,056,95112,494,481Jun 02
TANG KEVINDirectorMar 03 '26Buy14.22184,2082,619,43812,229,500Mar 03
TANG KEVINDirectorMar 02 '26Buy14.26199,3532,842,83312,045,292Mar 03
TANG KEVINDirectorFeb 27 '26Buy13.99516,4397,226,53511,845,939Mar 03
TANG KEVINDirectorAug 05 '25Buy11.68200,0002,336,00011,329,500Aug 05
TANG KEVINDirectorAug 04 '25Buy11.34100,0001,134,00011,129,500Aug 05
TANG KEVINDirectorAug 01 '25Buy10.121,000,00010,120,00011,029,500Aug 05
Keenan GregChief Medical OfficerAug 01 '25Sale10.5020,000210,000133,484Aug 05
Keenan GregChief Medical OfficerMar 07 '25Sale8.238,30568,350153,484Mar 07
TANG KEVINDirectorMar 04 '25Buy7.96748,0385,953,30410,029,500Mar 04
Robertson Stephen P.EVP, General CounselMar 04 '25Sale7.9257,607456,247509,276Mar 04
Miller Joseph MChief Financial OfficerMar 04 '25Sale7.9256,154444,740577,361Mar 04
Greenleaf PeterChief Executive OfficerMar 04 '25Sale7.92164,9471,306,3801,788,945Mar 04
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.